Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty

Faculty

Kelly F. Bell, PharmD, MSPhr

Director, Health Economics and Outcomes Research (at time of study)

AstraZeneca

Wilmington, Delaware

Devin M. Enhoffer, PharmD

Postdoctoral Fellow

Ernest Mario School of Pharmacy

Rutgers University

Piscataway Township, New Jersey

James M. Eudicone, MS, MBA

Director, Health Economics and Outcomes Research Statistics & Programming

AstraZeneca

Wilmington, Delaware

Sepehr Farahbakhshian, MS

Associate Director of Managed Markets

(at time of study)

AstraZeneca

Wilmington, Delaware

Ray Gani, PhD

Senior Research Scientist (at time of study)

IQVIA

Reading, Berkshire, United Kingdom

Jennifer B. Green, MD

Associate Professor of Medicine

Division of Endocrinology

Duke University Medical Center

Durham, North Carolina

Huan Huang, PhD

Scientific Advisor, Real-World Insights

IQVIA

Cambridge, Massachusetts

Michelle R. Krukas-Hampel, MA

Scientific Advisor, Advisory Analytics

IQVIA

Cambridge, Massachusetts

Keith Latham, PharmD

US Medical Affairs

AstraZeneca

Wilmington, Delaware

Carrie McAdam-Marx, PhD, MSCI, RPh

Associate Professor, Director

Pharmaceutical Evaluation & Policy Division

University of Arkansas for Medical Sciences (UAMS)

Little Rock, Arkansas

Cathy W. Tugwell, RN, BSN

Senior Regional Scientific Manager

(at time of study)

AstraZeneca

Wilmington, Delaware

Eric T. Wittbrodt, PharmD, MPH

Director, Health Economics

and Outcomes Research

US Medical Affairs

AstraZeneca

Wilmington, Delaware

Faculty Disclosures

The authors report relationships with the following organizations:

Kelly F. Bell, PharmD, MSPhr

EMPLOYMENT

GlaxoSmithKline

James M. Eudicone, MS, MBA

EMPLOYMENT

AstraZeneca

EMPLOYER CONFLICT OF INTEREST

AstraZeneca: Subject matter pertains to an AstraZeneca product

Sepehr Farahbakhshian, MS

EMPLOYMENT

Employment with AstraZeneca (at time of study)

STOCK OWNERSHIP

AstraZeneca

Ray Gani, PhD

CONSULTANT

AstraZeneca

EMPLOYMENT

Quintiles (at time of study), which received funding from AstraZeneca

Jennifer B. Green, MD

CONSULTANT

Boehringer Ingelheim Pharmaceuticals, Inc

Daiichi Sankyo Company, Limited

Merck Sharp & Dohme Corp

Novo Nordisk Inc

RESEARCH SUPPORT

AstraZeneca

GlaxoSmithKline plc

Intarcia Therapeutics, Inc

Huan Huang, PhD

EMPLOYMENT

IQVIA

EMPLOYER CONFLICT OF INTEREST

IQVIA, which received research funding to conduct study from AstraZeneca

Michelle R. Krukas-Hampel, MA

EMPLOYMENT

IQVIA

EMPLOYER CONFLICT OF INTEREST

IQVIA, which received research funding to conduct study from AstraZeneca

Keith Latham, PharmD

EMPLOYMENT

AstraZeneca

STOCK OWNERSHIP

AstraZeneca

Carrie McAdam-Marx, PhD, MSCI, RPh

RESEARCH SUPPORT

AstraZeneca

Sanofi

Eric T. Wittbrodt, PharmD, MPH

EMPLOYMENT

AstraZeneca

EMPLOYER CONFLICT OF INTEREST

AstraZeneca: Subject matter pertains to AstraZeneca products (an SGLT2 inhibitor [article 2] and a GLP-1 receptor agonist [articles 3 and 4])

Devin M. Enhoffer, PharmD, and Cathy W. Tugwell, RN, BSN, report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Leave a Reply

Your email address will not be published. Required fields are marked *